meta
|
evidence
COVID-19
Living systematic review and meta-analysis
***** adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
deaths
clinical improvement
clinical improvement (time to event analysis only)
death or ventilation
mechanical ventilation
off oxygenation
serious adverse events
adverse events
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance